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A B S T R A C T
Mobility and balance problems are common and often debilitating features of Huntington’s disease (HD).
In this exploratory study we aimed to investigate the inﬂuence of disease severity, severity of motor
deﬁcits, lower limb muscle strength, cognition, executive function, lean muscle mass and reactivity on
mobility and balance.
Twenty-two individuals with HD were recruited from the North Metropolitan Area Mental Health
Service, Perth, Australia. Pertinent demographic, genetic and disease progression information was
recorded prior to testing. Balance was assessed using dynamic and static balance tasks. Mobility was
assessed using self-paced and fast-paced mobility measures. Cognitive and executive measures were
used to assess verbal learning and memory, information processing speed, attention, response inhibition
and cognitive ﬂexibility. Lower limb muscle strength was evaluated by maximal isokinetic and isometric
voluntary contractions. Lean tissue mass was quantiﬁed using Dual-energy X-ray absorptiometry.
Reactivity was measured using Moyart equipment.
Univariate and multivariate linear regression statistical models were used to examine the inﬂuence of
these measures on mobility and balance. Univariate analyses showed that disease severity as well as
measures of information processing speed, attention, cognitive ﬂexibility, response inhibition and lower
limb strength, were strongly related with mobility and balance. Additionally multivariate analyses
showed that disease severity, cognitive ﬂexibility and knee ﬂexion strength together were better able to
explain mobility and balance performance than any single measure (50–85%).
In conclusion, our preliminary results suggest that as well as disease severity, cognitive and executive
impairment and reduced lower limb strength contribute signiﬁcantly to mobility and balance problems.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Problems with balance and mobility are commonly reported by
individuals suffering with HD. Problems occur early in the disease
course and worsen with disease progression [1]. Impairments in
balance and mobility often predict nursing home placement,
increase the likelihood for falls and can severely impact on health
related quality of life [2,3].
There are no clinically proven treatment strategies for
addressing balance and mobility problems in people with HD.* Corresponding author at: School of Medical Sciences, Edith Cowan University,
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3.0/).Previous studies examining mobility and balance in people with
HD have documented decreases in gait velocity and stride length,
increases in stride-to-stride variability, double support time and
step time, and increased postural sway [4–10]. While providing a
vivid description of mobility and balance issues, previous studies
have failed to investigate clinical features that contribute to
mobility and balance problems in HD.
Studies in people with Parkinson’s disease (PD) have reported
strong associations between muscle power and strength and
performance on balance and mobility tasks [11–13]. Task
dependent relationships between cognition and mobility and
balance have also been documented in PD [12]. Similar associa-
tions have been reported in people with multiple sclerosis (MS)
[14–17]. In the elderly, age related losses of lean tissue have been
reported to strongly predict mobility and balance problems [18].
Individuals with HD, in addition to displaying movementle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Table 1
Participant characteristics.
Variables Mean (SD) (n = 22) Range
Age (years) 50.85  9.24 30.3–70
Disease duration 3.95  4.26 0.3–17.3
CAG (n) 44.22  2.99 39–51
Disease burden score 427.22  118.05 269.5–596
UHDRS-Total Motor Score 26.45  12.41 5–45
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pairment [19–23] as well as skeletal muscle atrophy throughout
the disease course [24,25], which may similarly adversely impact
on balance and mobility.
Emerging evidence suggests that in HD, reduced muscle
strength, cognitive and executive problems as well as skeletal
muscle atrophy are remediable to interdisciplinary rehabilitation
approaches [25–27]. This exploratory study therefore aimed to
investigate the inﬂuence of motor, cognitive, executive and body
composition features of the disease on mobility and balance
performance in people with HD as a better understanding of the
contribution of these deﬁcits to balance and mobility may lead to
improved therapies in HD.
Materials and methods
Ethics approval
This study was approved by the Human Research Ethics
Committee at Edith Cowan University and the North Metropolitan
Area Mental Health Service (NMAMHS) Human Research Ethics
Committee. All participants provided written informed consent.
Participants
Sixty-two potential participants were identiﬁed using the
Neuroscience Unit database of the NMAMHS. Participants were
only included if they had received a positive genetic test, were
formally diagnosed as symptomatic (Uniﬁed Huntington’s Disease
Rating Scale Total Motor Score [UHDRS-TMS]  5), and had the
ability to follow verbal or written instruction. Participants were
not included if they had recent substance abuse, an unstable
psychiatric state, confounding neurological condition or concomi-
tant physical injury.
Study procedures
Participants were evaluated over two weekends at Edith Cowan
University using a variety of mobility and balance tasks as well as
cognitive, executive, lower limb muscle strength, lean tissue mass
and reactivity measures. All assessments were performed by
accredited independent examiners.
Outcome measures
Dynamic and static balance was examined using the berg
balance scale (BBS), sensory organisation test (SOT) and the
repeated sit to stand test (RSST). Mobility over short and long
distances was quantiﬁed using the timed walk test (TWT) and the
six minute walk test (6MWT) [28]. These measures have previously
been demonstrated to be reliable in individuals with HD [28,29].
Predictor measures
Disease severity and severity of motor abnormalities were
measured using the disease burden score and the UHDRS-TMS.
Cognition and executive function was examined using a variety of
clinically validated measures. The Hopkins Verbal Learning Test-
Revised (HVLT-R) was used to measure verbal learning and
memory [25,30]. Information processing speed and attention were
examined using the Symbol Digit Modalities Test (SDMT) [25,31].
Response inhibition and cognitive ﬂexibility were examined using
the Delis-Kaplan Executive Function System (D-KEFS) Colour Word
Interference Test (CWIT) and Trail Making Trials (TMT) [25].
Reactivity was measured using a visual response task. Dual-energy
X-ray absorptiometry (DEXA; Hologic Discovery A) was used toquantify lean tissue mass (g) [25]. Lower limb muscle strength was
quantiﬁed using a maximal voluntary isometric and isokinetic
knee ﬂexion and extension contractions with automated dy-
namometry (Biodex, System 3, USA). Isokinetic knee extension and
ﬂexion strength was examined using 1808 s1 (fast) and 308 s1
(slow) maximum voluntary contraction (MVC) test protocols.
Isometric knee extension and ﬂexion strength were also measured
at 608 ﬂexion. Individuals performed three maximal voluntary
contractions for each strength protocol.
Statistical analysis
Data are presented as mean, range and standard deviation (SD).
Associations between balance and mobility tasks (outcome
variables), disease severity, severity of motor abnormalities and
measures of cognition, executive function, lower limb strength,
lean tissue mass and reactivity (predictor variables) were
determined using univariate linear regression analysis. Associa-
tions between multiple predictor variables and balance and
mobility were then determined using multivariate linear regres-
sion. The results of the univariate linear regression analysis
showed that measures of disease severity, attention, information
processing speed, cognitive ﬂexibility and response inhibition
associated strongly with balance and mobility tasks. These
predictor variables were entered into a multivariate linear
regression model and assessed for association with each of the
mobility and balance tasks. Backward selection estimation was
then used to obtain the most signiﬁcant multivariate model.
Statistical signiﬁcance was set at p  0.05. All statistical analyses
were performed using STATA version 9.1.
Results
Of the sixty-two potential participants, twenty-two individuals
agreed to voluntarily participate in the study (Table 1.) Of these, 16
were taking antidepressants, 12 anti-psychotics and 5 anti-choreic
medications (Table 1). Demographic, disease severity, severity of
motor abnormalities, cognition, executive function, lower limb
strength, lean tissue mass, reactivity, mobility and balance data are
displayed in Tables 1 and 2.
Balance
Univariate analyses revealed signiﬁcant associations between
disease severity and performance on balance tasks (18–50.0% for
disease burden score). Moreover, measures of information
processing speed, attention, cognitive ﬂexibility, response inhibi-
tion and lower limb strength were signiﬁcantly associated with
performance on balance tasks (20.3–27% for correct oral, 18.2–
53.0% for word reading, 26.3–49.5% for motor speed, 24.5–42.7%
for 608 MVC knee ﬂexion; Tables A.1–A.3). Task dependent
associations between measures of verbal learning and memory
and performance on the RSST task were also found (total recall
21.3%). Lean tissue mass, reactivity and severity of motor
abnormalities were found not to be related to balance task
performance (Tables A.1–A.3).
Table 2
Study participant performance on outcome measures.




Correct written 26.33  10.57 10.00–48.00
Incorrect written 1.66  1.95 0.00–6.00
Correct oral 29.71  13.40 8.00–60.00
Incorrect oral 1.85  2.34 0.00–7.00
HVLT-R
Total recall 16.52  6.20 4.00–30.00
Delayed recall 5.13  2.35 1.00–9.00
Retention 77.00  22.59 33.00–129.00
Recognition discrimination
index
8.00  3.08 2.00–15.00
D-KEFS TMT
Visual scanning 35.42  15.83 16.00–70.00
Number sequencing 59.57  21.84 33.00–124.00
Letter sequencing 79.10  55.56 31.00–234.00
Number–letter sequencing 142.00  54.24 61.00–239.00
Motor speed 65.44  35.16 18.00–147.00
D-KEFS CWIT
Colour naming 44.05  15.72 22.00–78.00
Word reading 35.14  13.81 20.00–73.00
Inhibition 89.42  33.52 40.00–186.00
Lower limb strength measures
308 s1 MVC knee extension 127.23  54.36 40.80–217.10
1808 s1 MVC knee extension 71.05  29.92 20.90–128.45
308 s1 MVC knee ﬂexion 71.88  32.44 15.60–138.95
1808 s1 MVC knee ﬂexion 50.19  19.33 14.30–96.00
608 MVC knee extension 157.30  49.06 71.10–238.95
608 MVC knee ﬂexion 65.46  18.73 14.80–100.25
Body composition assessment
Lean tissue mass 52224.47  10332.29 34362.20–68907.30
Reactivity assessments
Visual reaction time (DOM) 0.69  0.24 0.34–1.20
Visual reaction time (NON) 0.67  0.25 0.26–1.21
Outcome variables
Balance assessments
SOT 54.04  15.63 22.00–80.00
BBS 46.59  7.83 26.00–56.00
RSST 28.62  12.76 12.00–64.00
Mobility assessments
TWT (fast-paced) 6.17  2.81 3.08–16.72
TWT (self-paced) 8.10  2.63 5.90–17.18
6MWT 466.19  127.37 87.00–630.00
DOM, dominant hand; NON, non-dominant hand.
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best explained by disease severity (disease burden score explained
57%; Table A.7). For the SOT, performance variability was best
explained by disease severity and cognitive ﬂexibility measures
(disease burden score and motor speed together explained 50% of
variability; Table A.7). Performance variability on the RSST was
best explained by measures of cognitive ﬂexibility and knee ﬂexion
muscle strength (motor speed and 608 MVC knee ﬂexion strength
together explained 72%; Table A.7)
Mobility
Univariate analyses showed signiﬁcant associations between
disease severity and performance of mobility tasks (disease burden
score 43–50%). Measures of attention, information processing speed,
cognitive ﬂexibility, response inhibition and lower limb strength
measures were also associated with mobility task performance
(correct oral 20–40.1%, word reading 34.1–52.2%, motor speed 26.7–
52.8%, 608 MVC knee ﬂexion strength 43–60%; Tables A.4–A.6). Task
dependent associations between verbal learning and memory and
mobility task performance were also evident (total recall, 19.5%;Tables A.4–A.6). There was no evidence of associations between lean
tissue mass, reactivity or severity of motor abnormalities and
performance on mobility tasks (Tables A.4–A.6).
Multivariate analyses revealed that when measures were
collectively considered, disease severity, cognitive ﬂexibility and
knee ﬂexion strength measures explained a signiﬁcantly greater
proportion of performance variability on mobility tasks than any
single measure (TWT-SP 85%, TWT-FP 72%, 6MWT 85%; Table A.7).
Discussion
This study found that disease severity, lower limb muscle
strength, cognition and executive function signiﬁcantly inﬂuenced
performance on balance and mobility tasks, while reactivity and
lean tissue mass did not. Furthermore, this study showed that
when all measures were collectively considered, the factors most
critically related to performance on balance and mobility tasks
were disease severity, cognitive ﬂexibility and knee ﬂexion
strength, and together these measures better explained balance
and mobility performance than any single measure.
An important ﬁnding of this study was that cognition and
executive function signiﬁcantly inﬂuenced performance on balance
and mobility tasks. Similar ﬁndings have been found in people
suffering from PD [12,32,33] and mild cognitive impairment (MCI)
[34]. Paul et al. [12,32] in two recent studies showed that executive
function and cognition signiﬁcantly inﬂuenced balance and falls in
people with PD. Persad et al. [34] in a similar study found that
cognition and executive function were strongly related tobalance and
mobility in people with MCI. These ﬁndings highlight that deteriora-
tion of cognitive and executive function adversely impacts upon
balance and mobility in people with neurodegenerative diseases.
The relationship of lower limb strength with balance and
mobility task performance was not unexpected. Interestingly
though, we found that relationships were often dependent on the
muscle group involved and the type of contraction performed, with
the 608 MVC knee ﬂexion measure demonstrating signiﬁcant
association with all balance and mobility tasks. Both 308 s1 MVC
knee ﬂexion and 1808 s1 MVC knee ﬂexion measures similarly
demonstrated strong associations with performance on mobility
tasks but not balance tasks. Broekmans et al. [35] in a similar study
found knee ﬂexion strength to strongly predict walking capacity in
people with MS. Knee ﬂexor involvement during stabilisation and
mobility tasks in healthy individuals is well established [36–38],
and likely explains our ﬁndings. Multidisciplinary interventions
have been shown to improve lower limb strength and perception of
balance in people with HD [25], therefore mobility and balance
problems may be amenable to such interventions.
As expected, a strong relationship was observed between
disease severity and performance on balance and mobility tasks,
indicating a signiﬁcant contribution of HD progression to
movement disability. Of interest, is the ﬁnding that severity of
motor abnormalities, as measured by the UHDRS-TMS, was not
signiﬁcantly associated with performance on balance and mobility
tasks. This ﬁnding has important clinical implications for the
assessment of balance and mobility in HD. It illuminates the
importance of identifying speciﬁc measures to supplement the
UHDRS-TMS that can more sensitively quantify balance and
mobility decrements.
Lean tissue mass and reactivity demonstrated negligible
associations with mobility and balance. This was an unexpected
ﬁnding, considering that studies in PD have reported reactivity and
lean muscle mass to be important clinical determinants of balance
and mobility performance [12,32,39]. Discrepancies between
ﬁndings are likely due to pathological and clinical differences
between PD and HD [40,41], as well as methodological and sample
size differences between the studies.
T. Cruickshank et al. / Basal Ganglia 4 (2014) 67–7070Our ﬁndings result from a relatively small sample of individuals
with manifest HD, most of whom were taking medication, as such
our ﬁndings should be interpreted with a degree of caution.
Conclusion
Here we provide preliminary evidence that disease severity,
lower limb weakness, cognitive impairment and executive
dysfunction signiﬁcantly inﬂuence mobility and balance in people
with HD. Moreover, we show that key clinical features, when
considered together, better explain performance on balance and
mobility tasks than any single measure. Findings while prelimi-
nary, provide insight into the multiple clinical features that
contribute to balance and mobility problems in HD, and provide a
venue for targeted multidisciplinary rehabilitation strategies.
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